Tamó R: Diagnosis and treatment of native joint infections

Török J: Diabetic foot infections: duration of antibiotic treatment after amputation

Brahier Th: Indications for surgery in vertebral osteomyelitis 

Vouloagka A: Diagnostic criteria, classification and treatment of fracture-related infections 

Pallanza M: DAIR in prosthetic joint infections: indications and risk factors for failure

Valente L: The role and evidence of rifampicin in prosthetic joint infections

Schumacher M: Are antibiotics “holidays” necessary before re-implantation in two-stage exchange of a prosthetic joint infection?

Gubser P: Which antibiotics penetrate well into the bone - what is the evidence?

Dörr T: Classification of skin and soft tissue infections and their risk factors

Bock L: Antibiotic treatment duration of skin and soft tissue infection

Turicchi G: How to prevent recurrent cellulitis

Calame A: The returning traveler with a skin ulcer on the leg

Tamó R: Diagnosis and treatment of native joint infections

Török J: Diabetic foot infections: duration of antibiotic treatment after amputation

Brahier Th: Indications for surgery in vertebral osteomyelitis
Vouloagka A: Diagnostic criteria, classification and treatment of fracture-related infections
Pallanza M: DAIR in prosthetic joint infections: indications and risk factors for failure

Valente L: The role and evidence of rifampicin in prosthetic joint infections

Schumacher M: Are antibiotics “holidays” necessary before re-implantation in two-stage exchange of a prosthetic joint infection?

Gubser P: Which antibiotics penetrate well into the bone - what is the evidence?

Dörr T: Classification of skin and soft tissue infections and their risk factors

Bock L: Antibiotic treatment duration of skin and soft tissue infection

Turicchi G: How to prevent recurrent cellulitis

Calame A: The returning traveler with a skin ulcer on the leg

Speaker: Tamara Dörr, HOCH Health Ostschweiz St. Gallen

Moderator: David Weller, University Hospital Zürich

Slides

Speaker: Adrien Calame, University Hospital Geneva

Moderator: Alice Berger, University Hospital Geneva

Perroud C: Should all patients with Staphylococcus aureus bacteremia undergo echocardiography?

Bernasconi N: Should PET/CT be incorporated as a standard component of the diagnostic workup for infective endocarditis in all patients with prosthetic valves or cardiac devices?

Manamel M: When should oral switch therapy, OPAT, or long-acting lipoglycopeptides be considered for the treatment of left-sided infective endocarditis?

Toppino S: Should rifampicin and gentamicin be used in prosthetic valve endocarditis caused by staphylococci?

Turicchi G: To give or not to give aminoglycoside in a septic patient?

Weller D: When to consider clindamycin and IVIG in a septic patient?

Mongiat M: Sepsis-3 in clinical practice: are the new definitions improving patient care?

Gubler M: When vancomycin should be added in an empiric treatment? 

Dias S: A patient transferred from a Greek ICU presents with sepsis. Which is the ideal empiric treatment?

Martischang R: Are 7 days enough for non-complicated bacteriemia by MDR or XDR Enterobacterales?

Monsalve L:What are the current treatment options (excluding page-therapy) for carbapenem resistant A. baumanii, MDR P. aeruginosa, carbapenemase-producing Enterobacterales

Perroud C: Should all patients with Staphylococcus aureus bacteremia undergo echocardiography?

Bernasconi N: Should PET/CT be incorporated as a standard component of the diagnostic workup for infective endocarditis in all patients with prosthetic valves or cardiac devices?

Manamel M: When should oral switch therapy, OPAT, or long-acting lipoglycopeptides be considered for the treatment of left-sided infective endocarditis?

Toppino S: Should rifampicin and gentamicin be used in prosthetic valve endocarditis caused by staphylococci?

Turicchi G: To give or not to give aminoglycoside in a septic patient?

Weller D: When to consider clindamycin and IVIG in a septic patient?

Mongiat M: Sepsis-3 in clinical practice: are the new definitions improving patient care?

Gubler M: When vancomycin should be added in an empiric treatment
Dias S: A patient transferred from a Greek ICU presents with sepsis. Which is the ideal empiric treatment?

Martischang R: Are 7 days enough for non-complicated bacteriemia by MDR or XDR Enterobacterales?

Monsalve L:What are the current treatment options (excluding page-therapy) for carbapenem resistant A. baumanii, MDR P. aeruginosa, carbapenemase-producing Enterobacterales

Speaker: Anna Mertelsmann, University Hospital Zürich

Moderator: David Weller, University Hospital Zürich

Not available

Speaker: Coline Sia-Herren, Inselspital Bern

Moderator: Eugénie Colin-Benoit, Inselspital Bern

Nicolas Benedict Gürtler, University Hospital Basel

Moderator Nina Khanna, University Hospital Basel

Slides

Speaker: Cécile Bessat, CHUV Lausanne

Moderator: Emeline Gauthiez, CHUV Lausanne

Slides

Mertelsmann A.; Risk factors for recurrent UTI and strategies for prevention

Vock I.; UTI with Candida spp.: risk factors and clinical management

Cordes Lourenço L.; Treatment of chronic prostatitis – which antibiotics and for how long?

Calame A. PRO; Baumgartner Ch. CON; Can we treat UTI with ESBL-producing enterobacterales with beta-lactam/beta-lactamase-inhibitors?

Gürtler N.; Oral antibiotic treatment options for abdominal abscesses and does the size of abscess influence the choice of antibiotic?

Magnenat E.; When shall we treat enterococci recovered from intra-abdominal samples?

Török J.; Diverticulitis: when do we need antibiotics and when not?

Heller S. PRO; Monsalve L. CON; Shall we treat intra-abdominal infections in contact with surgical nets as foreign body infections?

Krischer E. BLESSING; Tagini F. CURSE; Multiplex PCR stool diagnostic: a diagnostic curse or blessing?

Dörr T.; Risk factors for and prevention of C. difficile-associated diarrhea

Naudi G.; Diarrhea in the returning traveller – red flags

Roth-Müller A.; Diagnostic evaluation of chronic diarrhea in the immunosuppressed patient

Mertelsmann A.; Risk factors for recurrent UTI and strategies for prevention

Vock I.; UTI with Candida spp.: risk factors and clinical management

Cordes Lourenço L.; Treatment of chronic prostatitis – which antibiotics and for how long?

Calame A. PRO; Baumgartner Ch. CON; Can we treat UTI with ESBL-producing enterobacterales with beta-lactam/beta-lactamase-inhibitors?

Gürtler N.; Oral antibiotic treatment options for abdominal abscesses and does the size of abscess influence the choice of antibiotic?

Magnenat E.; When shall we treat enterococci recovered from intra-abdominal samples?

Török J.; Diverticulitis: when do we need antibiotics and when not?

Heller S. PRO; Monsalve L. CON; Shall we treat intra-abdominal infections in contact with surgical nets as foreign body infections?

Krischer E. BLESSING; Tagini F. CURSE; Multiplex PCR stool diagnostic: a diagnostic curse or blessing?

Dörr T.; Risk factors for and prevention of C. difficile-associated diarrhea

Naudi G.; Diarrhea in the returning traveller – red flags

Roth-Müller A.; Diagnostic evaluation of chronic diarrhea in the immunosuppressed patient

Bock L: Long-acting ART

Mongiat M: Lenacapravir

Pallanza M: Pregnancy & breast feeding

Leuenberger D: Novelties in OI management

Baarts J: PrEP

Barda B: Pros in adding statins in PWH

Marinosci A: Cons in adding statins in PWH

Dias S: Reasonable microbiological diagnostics for community acquired pneumonia 

Michel J: Treatment and duration for complicated pneumonia

Frei A: Mycoplasma: Role of treatment - always necessary? Which treatment? 

Ciullini L: RSV vaccine in adults- is there an indication?

Schläppi C: RSV in children - recommendations for vaccination and monoclonal antibodies

Baumann M: Pertussis: current situation

Bock L: Long-acting ART

Mongiat M: Lenacapravir

Pallanza M: Pregnancy & breast feeding

Leuenberger D: Novelties in OI management

Baarts J: PrEP

Barda B: Pros in adding statins in PWH

Marinosci A: Cons in adding statins in PWH

Dias S: Reasonable microbiological diagnostics for community acquired pneumonia 

Michel J: Treatment and duration for complicated pneumonia

Frei A: Mycoplasma: Role of treatment - always necessary? Which treatment? 

Ciullini L: RSV vaccine in adults- is there an indication?

Schläppi C: RSV in children - recommendations for vaccination and monoclonal antibodies

Baumann M: Pertussis: current situation

Tamò R: Early onset sepsis

Bisch J: Late onset sepsis

Jaboyedoff M: Exanthematous childhood diseases

Obama B: Acute otitis media, group A streptococcal pharyngitis, sinusitis and rationale use of antibiotics

Altermatt B: Upper & lower respiratory tract infection & community acquired pneumonia in young children 

Dörr T: Vertical infection by intrauterine (type rubella) and peripartal (type hepatitis B) transmission 

Martin Y: Vertical CMV infection 

Magnenat E: Define catch-up vaccination plan in immigrants 

Mayer F: Immunisation of children with co-morbidities 

Tamò R: Early onset sepsis

Bisch J: Late onset sepsis

Jaboyedoff M: Exanthematous childhood diseases

Obama B: Acute otitis media, group A streptococcal pharyngitis, sinusitis and rationale use of antibiotics

Altermatt B: Upper & lower respiratory tract infection & community acquired pneumonia in young children

Dörr T: Vertical infection by intrauterine (type rubella) and peripartal (type hepatitis B) transmission

Martin Y: Vertical CMV infection

Magnenat E: Define catch-up vaccination plan in immigrants

Mayer F: Immunisation of children with co-morbidities 

Speaker: Carla Walti, Basel University Hospital

Moderator: Michelle Baumann, Basel University Hospital

Basilice Obama, Geneva University Hospital

Moderator: Hélène Buvelot, Geneva University Hospital

Gauthiez Emeline, CHUV Lausanne

Moderator Florian Desgranges, CHUV Lausanne

Vock I: Diagnosis and treatment of central-line-associated bloodstream infections (CLABSI) - pathogen-/patient-specific approaches 

Gauthiez E: Diagnosis and treatment of catheter-associated urinary tract infections (CAUTI) - when to treat bacteria in the urine? 

Tamo R: Diagnosis and treatment of C.difficile infections? – old and new options 

Gubler M: Contact isolation for patients with C.difficile infections? - PRO
Hirsch B: Contact isolation for patients with C.difficile infections? - CON

Gürtler N: New antibiotics against multidrug-resistant Gram-negative bacteria - mechanisms, spectrum and on-/off-label indications

Begré L: How to deal with presumed penicillin allergy in patients needing antibiotics?

Barda B: Therapeutic drug monitoring during antibiotic treatment? PRO

Weller D: Therapeutic drug monitoring during antibiotic treatment? CON

Bloch N: Diagnosis and empirical treatment of pulmonary invasive fungal infections in hem-onc patients 

Cancela-Costa A: Imaging characteristics of invasive pulmonary aspergillosis in neutropenia vs. corticosteroid-treatment vs. critically ill (ICU) patients 

Erba A: Aspergilloma in lung parenchyma, bronchus and sinus 

Monsalve L: The corticosteroid paradox: risk factor for invasive aspergillosis but beneficial adjunct treatment in allergic bronchopulmonary aspergillosis 

Roth-Müller: Indication for retinal examination in candidemia - PRO

Musumeci S: Indication for retinal examination in candidemia - CON 

Dörr T: Sino-orbito-cerebral mucormycosis 

Waldmann I: Cutaneous manifestations of invasive fungal infections

Vock I: Diagnosis and treatment of central-line-associated bloodstream infections (CLABSI) - pathogen-/patient-specific approaches 

Gauthiez E: Diagnosis and treatment of catheter-associated urinary tract infections (CAUTI) - when to treat bacteria in the urine? 

Tamo R: Diagnosis and treatment of C.difficile infections? – old and new options 

Gubler M: Contact isolation for patients with C.difficile infections? - PRO
Hirsch B: Contact isolation for patients with C.difficile infections? - CON

Gürtler N: New antibiotics against multidrug-resistant Gram-negative bacteria - mechanisms, spectrum and on-/off-label indications

Begré L: How to deal with presumed penicillin allergy in patients needing antibiotics?

Barda B: Therapeutic drug monitoring during antibiotic treatment? PRO

Weller D: Therapeutic drug monitoring during antibiotic treatment? CON

Bloch N: Diagnosis and empirical treatment of pulmonary invasive fungal infections in hem-onc patients 

Cancela-Costa A: Imaging characteristics of invasive pulmonary aspergillosis in neutropenia vs. corticosteroid-treatment vs. critically ill (ICU) patients 

Erba A: Aspergilloma in lung parenchyma, bronchus and sinus 

Monsalve L: The corticosteroid paradox: risk factor for invasive aspergillosis but beneficial adjunct treatment in allergic bronchopulmonary aspergillosis 

Roth-Müller: Indication for retinal examination in candidemia - PRO

Musumeci S: Indication for retinal examination in candidemia - CON

Dörr T: Sino-orbito-cerebral mucormycosis

Waldmann I: Cutaneous manifestations of invasive fungal infections

Speaker: Mikaël Tognon, Geneva University Hospital

Moderator: Annabelle Roth-Müller, Geneva University Hospital

Speaker: Claudine Reiber, Zurich University Hospital
Moderator: Tilman Obenhuber, Zurich University Hospital

Speaker: Lukas Baumann, Inselspital

Moderator: Martin Gubler, Inselspital

Speaker: Michelle Baumann, Basel University Hospital

Moderator: Carla Walti

Speaker: Véronique Suttels, CHUV Lausanne

Moderator: Florian Desgranges

Musumeci S: Diagnosis and treatment of vascular infections without graft material

Acevedo C: Diagnosis and treatment of vascular infections with graft material

Baumann M: Microbiological epidemiology of infective endocarditis

Cancela A: MRI, CT, PET for IE diagnosis: when and why?

Grimm K: Oral antibiotic treatment of IE – PRO

Padrutt M: Oral antibiotic treatment of IE – CON

Suttels C: Identifying sepsis in the hospital: New biomarkers

Capoferri G: Effective management: show us the evidence

Reinhold I: New treatments

Urwyler P: Measures to prevent the spread of resistant bacteria in the hospital

Tognon M: S. aureus decolonisation: when and how?

Bauer S: Selective digestive decontamination in the ICU or prior to colorectal surgery - PRO

Buvelot H: Selective digestive decontamination in the ICU or prior to colorectal surgery - CON

Toppino S: Antibiotic Stewardship: the shorter the better, where is the limit?

Barda B, Ciullini L: The 2023 Swiss survey on antibiotic stewardship in your hospital: ID physicians in training perspective

Musumeci S: Diagnosis and treatment of vascular infections without graft material

Acevedo C: Diagnosis and treatment of vascular infections with graft material

Baumann M: Microbiological epidemiology of infective endocarditis

Cancela A: MRI, CT, PET for IE diagnosis: when and why?

Grimm K: Oral antibiotic treatment of IE – PRO

Padrutt M: Oral antibiotic treatment of IE – CON

Suttels C: Identifying sepsis in the hospital: New biomarkers

Capoferri G: Effective management: show us the evidence

Reinhold I: New treatments

Urwyler P: Measures to prevent the spread of resistant bacteria in the hospital

Tognon M: S. aureus decolonisation: when and how?

Bauer S: Selective digestive decontamination in the ICU or prior to colorectal surgery - PRO

Buvelot H: Selective digestive decontamination in the ICU or prior to colorectal surgery - CON

Toppino S: Antibiotic Stewardship: the shorter the better, where is the limit?

Barda B, Ciullini L: The 2023 Swiss survey on antibiotic stewardship in your hospital: ID physicians in training perspective

Stefano Musumeci, Geneva University Hospital

Erba A:Meningoencephalitis, structured case presentation

Bargetzi A: State of the art overview with emphasis on diagnostics and empirical therapy

Bosetti D, Walti C: Controversy: Is a CT/MRI needed in every case? And when?

Bisch J; Epprecht J: Controversy 2: Should steroids be added to the therapy in every case?

AK: Brain abscess, structured case presentation

Cobuccio L: Approach to a patient with suspected brain abscess: diagnosis, empirical therapy

Chedid M, Van Singer M: Controversy: Should an etiological diagnosis (sampling) be pursued in all patients?

Mayer F: When is cardio-vascular surgery safe in a patient with endocarditis complicated by brain abscesses? 

Erba A:Meningoencephalitis, structured case presentation

Bargetzi A: State of the art overview with emphasis on diagnostics and empirical therapy

Bosetti D, Walti C: Controversy: Is a CT/MRI needed in every case? And when?

Bisch J; Epprecht J: Controversy 2: Should steroids be added to the therapy in every case?

AK: Brain abscess, structured case presentation

Cobuccio L: Approach to a patient with suspected brain abscess: diagnosis, empirical therapy

Chedid M, Van Singer M: Controversy: Should an etiological diagnosis (sampling) be pursued in all patients?

Mayer F: When is cardio-vascular surgery safe in a patient with endocarditis complicated by brain abscesses?

Padrutt M: Differential diagnosis of a brain lesion in HIV

Musumeci St: Differential diagnosis of a brain lesion after SOT and HSCT

Rüfenacht S; Diagnostics in native joint infections vs. prosthetic joint infections

Tognon M; Treatment concepts in prosthetic joint infections vs. fracture-related infections

Wimmersberger D; Microbiology and diagnostic approach 
in hematogenous vs. postoperative vertebral osteomyelitis

Baumann M; Pathophysiology and treatment of 
diabetic foot osteomyelitis vs. sacral osteomyelitis from pressure ulcers

Bargetzi A; Timing of tissue sampling in suspected implant infection: before or after antibiotic prophylaxis?

Höschel Th; Antibiotic holiday before re-implantation of a new prosthesis in two-stage exchange? PRO

Baumann L; Antibiotic holiday before re-implantation of a new prosthesis in two-stage exchange? CONTRA

Capoferri G; Oral vs. intravenous treatment for bone-/joint infections: if and when to switch?

Stavropoulou E; Evidence on treatment duration of bone infections

Seneghini M; Clinical and imaging characteristics of bone infection due to Tb vs. “conventional” bacteria
Obenhuber T; Tb IRIS vs. paradoxical (upgrade) reactions
Musumeci St; New treatment regimens for MDR/XDR-TB

Walti C; When to use adjunctive corticosteroids in Tb treatment?

Faré P; Risk factors for reactivation of LTBI
Rochat-Stettler L; Treatment of latent Tb infection: preferred regimen and expected efficacy
Lardelli P; High-dose rifampicin for Tb meningitis, PRO
Nawej-Tshikung O; High-dose rifampicin for Tb meningitis , CONTRA

Münst L: Treatment of uncomplicated/complicated UTIs

Boschung L: Treating uncomplicated UTIs without antibiotics

Vingerhoets S: Treating uncomplicated UTIs without antibiotics

Rüfenacht S: Prophylaxis of recurrent UTI 

Urwyler P: Controversies on asymptomatic bacteriuria

Stavropoulou E: ESBL in UTI: Epidemiology, risk factors and management 

Albrecht S: Prevention of catheter-associated UTIs 

West E: Diagnostic challenges of chronic prostatitis

Demars Y: LGV: pitfalls 

Abi Aad Y: Pelvic inflammatory diseases: key messages

Nawej O: Neuro-Syphilis: diagnosis and management

Faré P: Syphilis quiz

Wanner K: How do you treat Gonorrhoea and discuss controversial issues  

Geib V: Screening of Chlamydia in asymptomatic females 

Burgener A-V: Screening of Chlamydia in asymptomatic females 

Seneghini M: Diarrhea in the Returning Traveller – red flags

Tognon M: Infectious chronic diarrhea: case presentation

Münst L: Treatment of uncomplicated/complicated UTIs

Boschung L: Treating uncomplicated UTIs without antibiotics

Vingerhoets S: Treating uncomplicated UTIs without antibiotics

Rüfenacht S: Prophylaxis of recurrent UTI 

Urwyler P: Controversies on asymptomatic bacteriuria

Stavropoulou E: ESBL in UTI: Epidemiology, risk factors and management 

Albrecht S: Prevention of catheter-associated UTIs 

West E: Diagnostic challenges of chronic prostatitis

Demars Y: LGV: pitfalls 

Abi Aad Y: Pelvic inflammatory diseases: key messages

Nawej O: Neuro-Syphilis: diagnosis and management

Faré P: Syphilis quiz

Wanner K: How do you treat Gonorrhoea and discuss controversial issues  

Geib V: Screening of Chlamydia in asymptomatic females 

Burgener A-V: Screening of Chlamydia in asymptomatic females 

Seneghini M: Diarrhea in the Returning Traveller – red flags

Tognon M: Infectious chronic diarrhea: case presentation

Ses1: Sava M, Community acquired respiratory tract infections: diagnostics and treatment

Ses1: Piezzi V, Ventilator associated pneumonia: prevention and treatment

Ses1: Buvelot H, Chronic bacterial respiratory tract colonization: when and how to treat

Ses1: Mono versus combination therapy for complicated VAP 

Grp A: Pro by Rüfenacht J S, Cons by Filippidis P 

Grp B: Pro by Seneghini M, Cons by Munting A

Ses1: Controversies on respiratory tract infections

Grp A: Questions & discussion by Schärer V

Grp B: Questions & discussion by Frey A C

Ses2: Ragozzino S, Intra-abdominal abscesses: etiology, diagnostics and treatment

Ses2: D’Incau S, Acute pancreatitis: when and how do I treat with antimicrobials?

Ses2: Antifungal prophylaxis in the complicated ICU patient 

Grp A: Pro by Nawej O, Cons by Thoma R 

Grp B: Pro by Demars Y, Cons by Reiber C

Ses2: Controversies on intra-abdominal infections

Grp A: Questions & discussion by Neumayr A

Grp B: Questions & discussion by Morgenstern L

Ses1: Sava M, Community acquired respiratory tract infections: diagnostics and treatment

Ses1: Piezzi V, Ventilator associated pneumonia: prevention and treatment

Ses1: Buvelot H, Chronic bacterial respiratory tract colonization: when and how to treat

Ses1: Mono versus combination therapy for complicated VAP 

Grp A: Pro by Rüfenacht J S, Cons by Filippidis P 

Grp B: Pro by Seneghini M, Cons by Munting A

Ses1: Controversies on respiratory tract infections

Grp A, B: Questions & discussion by Schärer V & Frey A C

Ses2: Ragozzino S, Intra-abdominal abscesses: etiology, diagnostics and treatment

Ses2: D’Incau S, Acute pancreatitis: when and how do I treat with antimicrobials?

Ses2: Antifungal prophylaxis in the complicated ICU patient 

Grp A: Pro by Nawej O, Cons by Thoma R

Grp B: Pro by Demars Y, Cons by Reiber C

Ses2: Controversies on intra-abdominal infections

Grp A: Questions & discussion by Neumayr A

Grp B: Questions & discussion by Morgenstern L

Ses1: Nguyen A, Infections in neutropenic patients, case presentation

Ses1: Scheier T, Infections in neutropenic patients, overview

Ses1 grp A: Desgranges F, controversies 1, controversies 2

Ses1 grp B: Zingg S, controversies 1, controversies 2

Ses2: Wipf M, Antifungal prophylaxis neutropenic patients, case presentation

Ses2: Portillo V, Pro

Ses2: Papadimitriou M, Cons

Ses2 grp A: Scanferla G, controversies

Ses2 grp B: Kuster S, controversies

Ses3: Colin-Benoit E, Infections SOT, case presentation

Ses3: Sumer J, Infections SOT, overview

Ses3: Al Khalil O, Case

Ses3 grp A: Bosetti D, controversies

Ses3 grp B: Müller A, controversies

Ses4: Zanella MC, Antiviral prophylaxis SOT, case presentation

Ses4: Adam K M, Pro

Ses4: Hofmann E, Cons

Ses4 grp A: Haefliger D, controversies

Ses4 grp B: Durovic A, controversies

Ses1: Nguyen A, Infections in neutropenic patients, case presentation

Ses1: Scheier T, Infections in neutropenic patients, overview

Ses1 grp A: Desgranges F, controversies 1, controversies 2

Ses1 grp B: Zingg S, controversies 1, controversies 2

Ses2: Wipf M, Antifungal prophylaxis neutropenic patients, case presentation

Ses2:Portillo V, Pro

Ses2: Papadimitriou M, Cons

Ses2 grp A: Scanferla G, controversies

Ses2 grp B: Kuster S, controversies

Ses3: Colin-Benoit E, Infections SOT, case presentation

Ses3: Sumer J, Infections SOT, overview

Ses3: Al Khalil O, Case

Ses3 grp A: Bosetti D, controversies

Ses3 grp B: Müller A, controversies

Ses4: Zanella MC, Antiviral prophylaxis SOT, case presentation

Ses4: Adam K M, Pro

Ses4: Hofmann E, Cons

Ses4 grp A: Haefliger D, controversies

Ses4 grp B: Durovic A, controversies